Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Caijin Lin"'
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 5, Pp 400-415 (2024)
Objective: Mammographic calcifications are a common feature of breast cancer, but their molecular characteristics and treatment implications in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer
Externí odkaz:
https://doaj.org/article/e3bc9c83ef27494cb38ea30417eb3846
Autor:
Jing Yu, Caijin Lin, Jiahui Huang, Jin Hong, Weiqi Gao, Siji Zhu, Lin Lin, Xiaosong Chen, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Jiayi Wu, Kunwei Shen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The 21-gene recurrence score (RS) can predict chemotherapy benefit in estrogen receptor-positive, human epidermal growth factor receptor-2-negative (ER+/HER2-) early breast cancer patients. Age would influence the interaction betw
Externí odkaz:
https://doaj.org/article/246f454aa0eb46599ed8345543811441
Publikováno v:
Cancer Research. 83:P1-09
Background: Salvage mastectomy is traditionally recommended for patients who developed ipsilateral breast tumor recurrence (IBTR) in light of the previous breast irradiation. However, it remains controversial whether surgical axillary staging (SAS) i
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe prognosis of lymph node-negative triple-negative breast cancer (TNBC) is still worse than that of other subtypes despite adjuvant chemotherapy. Reliable prognostic biomarkers are required to identify lymph node-negative TNBC patients at
Externí odkaz:
https://doaj.org/article/42a66932abec4bfea108a72912254403
Autor:
Deyue Liu, Jiayi Wu, Caijin Lin, Shuning Ding, Shuangshuang Lu, Yan Fang, Jiahui Huang, Jin Hong, Weiqi Gao, Siji Zhu, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu
Publikováno v:
Cancers, Vol 14, Iss 13, p 3221 (2022)
Background: In adjuvant settings, epirubicin and cyclophosphamide (EC) and docetaxel and cyclophosphamide (TC) are both optional chemotherapy regimens for lymph node-negative, hormone receptor (HR)-positive, human epidermal receptor 2 (HER2)-negative
Externí odkaz:
https://doaj.org/article/aa76750dd6ed449394545f0dbd3e5504
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundMetastatic breast cancer (MBC) is a highly heterogeneous disease and bone is one of the most common metastatic sites. This retrospective study was conducted to investigate the clinical features, prognostic factors and benefits of surgery of
Externí odkaz:
https://doaj.org/article/d324fe5cdd9e41478d8f47f96bb17633
Autor:
Caijin Lin, Jiayi Wu, Lin Lin, Xiaochun Fei, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Despite low aggressiveness in tumor biology and high responsiveness to endocrine therapy, subgroups of patients with estrogen receptor-positive/HER2-negative (ER+/HER2-) breast cancer relapse early in the first two years after initiation
Externí odkaz:
https://doaj.org/article/700ec9f757594ad3958016f1dad6e01f
Autor:
Shuning Ding, Yu Zong, Caijin Lin, Lisa Andriani, Weilin Chen, Deyue Liu, Weiguo Chen, Yafen Li, Kunwei Shen, Jiayi Wu, Li Zhu
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Purpose: The objective of this study was to evaluate the American Joint Committee on Cancer (AJCC) pathological prognostic stage among patients with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) and to propose a modified score
Externí odkaz:
https://doaj.org/article/6042fe3417714e4ab4033abf869ada0f
Autor:
Caijin Lin1, Jiayi Wu1, Shuning Ding1, Chihwan Goh1, Lisa Andriani1, Kunwei Shen1, Li Zhu1 zhuli8@yeah.net
Publikováno v:
Cancer Research & Treatment. Apr2020, Vol. 52 Issue 2, p552-562. 11p.
Autor:
Li Zhu, Shuning Ding, Ou Huang, Weiguo Chen, Yafen Li, Weilin Chen, Xiaosong Chen, Jiayi Wu, Mengdi Chen, Caijin Lin, Deyue Liu, Kunwei Shen, Lisa Andriani, Jianrong He
Publikováno v:
Clinical Breast Cancer. 22:e147-e156
BACKGROUND In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, emerging evidence imply that clinical behaviors differ according to hormone receptor (HR) status. However, there is no conclusion about the relevance between estrog